Tuesday, January 27, 2009

Red Reef Laboratories International, Inc. (RRLB) Finds Gold in Diversification

DEERFIELD BEACH, FL and NAPOLEONVILLE, LA--(MARKET WIRE)--Jan 23, 2009 -- Red Reef Laboratories International, Inc. (Other OTC:RRLB.PK - News), a diversified scientific research, development, and marketing group, announces Versace Direct LLC, a wholly owned subsidiary of Red Reef Labs, launches "FAT PETER," an exclusive line of "lifestyle" supplement products targeted toward the Gay, Bi and Trans-gender community.
The wired GBT population is of interest because it has been characterized as the "marketer's dream audience."

According to the Commercial Closet Association, the American market today is estimated to be valued at $660 billion, projected to reach $835 billion by 2011 -- based primarily on U.S. population growth and steady 7% representation of gays and lesbians within the overall population.

The majority of gay households are comprised of what the Census Bureau coined "DINKs" -- Dual Income, No Kids.

Simmons' research, comparing US gay consumers to the national index of consumers, reported that its group was 71% male and 29% female, twice as likely as the national index to be professionals or managers and have a household income over US$60K (indeed twice as likely to have household income over US$250K), twice as likely to have a degree, three times more likely to be online than the average consumer, four times as likely to spend over US$150 on long distance and twice as likely to spend US$250 on mobile phone services.

Versace Direct LLC will build name recognition for its "Fat Peter" brand through the use of advertising media concentrated in the Greater Fort Lauderdale area, with special emphasis in the Village of Wilton Manors. Statistics consistently show that gay tourism generates over a billion dollars annually into the local economies. Wilton Manors and area businesses cater to this market with hotels, spas, restaurants, bars, nightclubs and health clubs and tourists have consistently flocked to enjoy the amenities 12 months a year.

To participate in this market opportunity, Versace Direct plans to advertise on the gay oriented WEBSITES and in magazines, newspapers, tourism guides, etc., and to translate the resulting product identity to the internet. The Fat Peter website will allow repeat customers as well as new customers to access the product line nationally and even internationally. This proven method for building brand loyalty is extremely cost effective due to its ability to pinpoint and focus on the target audience.

"Teaser" ads will begin to appear in the Wilton Manors area February 15th.

The plan is to increase brand recognition by duplicating the advertising program with local media in predominately gay communities within major American cities, initially in the South East, and expand to the North East, Central and Western states, and as revenues permit, South America and Europe. Many of the print media we advertise in publish in gay communities within most American cities, and offer reduced rates for advertising as we expand, while at the same time provide statistical support for introducing new markets.

As cross marketing opportunities arise, such as with MyoTrend Nutritional Products LLC outlets, Red Reef's experienced marketing team will be in a position to take full advantage to enhance distribution and sales for both divisions.

About Red Reef Laboratories International, Inc.:

Red Reef Laboratories International, Inc. is a diversified scientific research, development, and marketing group established to assemble, develop, commercialize and bring to market a variety of products. The first series of products combines advanced surfactant technology and increasingly "green" compounds to create specialized formulas for the disinfection and decontamination of equipment and surfaces. A second series of products has been developed which are specially formulated nutritional items for the health and wellness industry. For more information, please visit the Company's web site at www.redreef.biz

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

With the exception of historical information, the statements set forth above include forward-looking statements that involve risk and uncertainties. The Company wishes to caution readers that a number of important factors could cause actual results to differ materially from those in the forward-looking statements. Those factors include, but are not limited to, the risk factors noted in the Company's filings with the United States Securities and Exchange Commission, such as the rapidly changing nature of technology, evolving industry standards and frequent introductions of new products, services and enhancements by competitors; the competitive nature of the markets for the Company's products and services; the Company's ability to gain market acceptance for its products and services; the Company's ability to fund its operational growth; the Company's ability to attract and retain skilled personnel; the Company's ability to diversify its revenue streams and customer concentrations; and the Company's reliance on third-party suppliers.

Thursday, January 22, 2009

BEHL - One of the Largest Poultry Companies in USA Requested Algae Samples From BioCentric Energy Algae for Feedstock Utilization Analyses

HUNTINGTON BEACH, CA--(MARKET WIRE)--Jan 22, 2009 -- BioCentric Energy Algae, wholly owned subsidiary of BioCentric Energy Holdings Inc. (Other OTC:BEHL.PK - News), has received a request from one of the largest poultry companies in the USA to provide them with samples of our algae for testing for possible utilization of high-grade feedstock with Omega 3.
Dennis Fisher, Board Member and President for BioCentric Energy Inc. (BEHL), stated today, "We are pleased to provide this multi-billion dollar company our algae as this will independently verify what I have stated all along... in today's market, the algae grown in our closed loop photobioreactors has a greater value as a high grade feedstock, rich in Omega 3, than as the premier building block for biodiesel. We can get almost three times payment for quality Omega 3 feedstock as we can for biodiesel feedstock." Mr. Fisher went on to say, "And, I believe Our Algae Solution is also one of the answers to reduce CO2 emissions profitably."

The Team of BioCentric Energy Algae deliver cost effective photobioreactor systems that take the emissions from smoke stacks, and in a closed loop environment, grow algae for production and harvest profitably.

BioCentric Energy Holdings, Inc. is dedicated to the development of new technologies as well as acquiring and fostering companies with innovative technologies designed to provide unique and effective green energy solutions for the 21st century. Along with the cultivation of important relationships and partnerships with synergistic entities, BioCentric Energy has devoted substantial time and effort in research and development in order to bring a range of innovative green alternatives to the marketplace.

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of the Company's products, the competitive environment within the industry, the ability of the Company to continue to expand its operations, the level of costs incurred in connection with the Company's expansion efforts, economic conditions in the industry and the financial strength of the Company's customers and suppliers. The Company does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Wednesday, January 21, 2009

BioCentric Energy Holdings, Inc. Announces Management Changes -- Dennis Fisher and Dennis Shen Appointed as Board Members

HUNTINGTON BEACH, CA--(MARKET WIRE)--Jan 21, 2009 -- BioCentric Energy, Inc. has appointed both Dennis Fisher and Dennis Shen as board members for BioCentric Energy Holdings (Other OTC:BEHL.PK - News). As part of the merger agreement Mr. Dan Motsinger shall be resigning as both a board member and as President. Mr. Fisher shall also be placed as President of BEHL.
Dennis Fisher, Board Member and President for BioCentric Energy, Inc., stated today," For a number of years we have been building Our Unique Green Team which consists of proven capable and successful professionals that are and have been committed to delivering our country and our planet a profitable path to reduce global warming." Mr. Fisher went on to say, "Approximately one third of the CO2 Green House Gas Emissions are directly attributed to the production of energy in our country (http://fossil.energy.gov/programs/sequestration/publications/programplans/2005/sequestration_roadmap_2005.pdf). Our primary focus is the delivery of our low cost photobioreactor systems that take the emissions from smoke stacks and, in a closed loop environment, grow algae for production and harvest."

BioCentric Energy, Inc., subsidiary of BioCentric Energy Holdings Inc., is dedicated to the development of new technologies as well as acquiring and fostering companies with innovative technologies designed to provide unique and effective green energy solutions for the 21st century. Along with the cultivation of important relationships and partnerships with synergistic entities, BioCentric Energy has devoted substantial time and effort to research and development in order to bring a range of innovative green alternatives to the marketplace.

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of the Company's products, the competitive environment within the industry, the ability of the Company to continue to expand its operations, the level of costs incurred in connection with the Company's expansion efforts, economic conditions in the industry and the financial strength of the Company's customers and suppliers. The Company does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Tuesday, January 20, 2009

Proton Laboratories Discusses Salmonella and Anti-Microbial Safety With Proton's Electrolyzed Water

ALAMEDA, CA--(MARKET WIRE)--Jan 20, 2009 -- Proton Laboratories Inc. (Other OTC:PLBI.PK - News)
At a conference in San Diego, California, Jim Wheeler, President & CEO of Proton labs discussed the recent outbreak of salmonella across the United States, and how if the peanuts had been washed with Proton's electrolyzed water this would not have happened. Proton Laboratories is a biotechnology company that develops GREEN solutions utilizing electrolyzed water for both residential and commercial applications.

Jim Wheeler, President and CEO of Proton, said, "Minnesota health officials issued a product alert for peanut butter on Friday after finding a jar that was contaminated with a strain of salmonella linked to an outbreak across the United States. The outbreak of salmonella food poisoning has sickened at least 399 people and put 70 or more into hospitals since September." Jim also said, "Proton has invested heavily in the area of health and wellness and it is a shame that people are still sick and dying of something that is so easily eliminated."

Founded in 2003, Proton has developed and manufactures advanced water technology for the Drinking Water, Medical, Agricultural, Food Preparation and Mining Industries.

About Proton Laboratories Inc.

Based in Northern California, Proton Laboratories is a GREEN biotechnology company that develops new practical applications for electrolyzed water. The company alters the properties of water via electrolysis with electrolyte separation. Based upon proven technology, science, engineering, product design, and products that have been successfully developed over the past decade. For more information, please visit our website at www.protonlabs.com, or contact our Investor Relations Department at 1-888-548-3002.

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to acquire and develop specific projects, the ability to fund operations and changes in consumer and business consumption habits and other factors over which Proton Laboratories, Inc. has little or no control.

Monday, January 19, 2009

Proton Laboratories Introduces Its Proprietary Cooling Tower Process

ALAMEDA, CA--(MARKET WIRE)--Jan 16, 2009 -- Proton Laboratories Inc. (Other OTC:PLBI.PK - News), a biotechnology company that develops practical uses for electrolyzed water, is pleased to introduce its proprietary cooling tower maintenance equipment.
"The advanced electrolysis process that was engineered and built by Proton Laboratories and its Japanese partners provides users of cooling towers a highly effective, non-chemical, non-toxic method of removing scale buildup in cooling towers and heat exchange systems and then preventing scale in the future," states Jim Wheeler, CEO.

The system was introduced into the Japanese industrial market with a high acceptance due to the improved productivity of their processes and significant savings in energy and chemicals and reduced equipment downtime. As more of the industrialized countries move away from their dependence on chemical maintenance methods, Proton Laboratories is providing a viable option to commercial and industrial users of cooling towers and heat exchangers. The Facilities Managers in Japan have noted that the considerable benefits that are attained by this system can be quantified with regards to lower ongoing maintenance costs, less down times, improved productivity and the impressive overall quality gains. Additionally, growing concerns over ground water contamination from the disposal of toxic chemicals, used to maintain cooling towers, provides a strong need for a technology of this caliber.

About Proton Laboratories Inc.

Based in Northern California, Proton Laboratories is a biotechnology company that develops breakthrough practical applications for electrolyzed water. The company alters the properties of water via electrolysis with electrolyte separation. Based upon proven technology, science, engineering, product design, and products that have been successfully developed by our Japanese partners, Proton Laboratories will expand the marvel of electrolyzed water throughout the world. For more information, please visit our website at www.protonlabs.com.

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to acquire and develop specific projects, the ability to fund operations and changes in consumer and business consumption habits and other factors over which Proton Laboratories Inc. has little or no control.

Wednesday, January 14, 2009

Hard To Treat Diseases (HTDS) in Merger Talks with Mellow Hope, China

SHENZHEN, China, Jan. 14 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com management representatives are currently in China negotiating a merger agreement with Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (Mellow Hope).
Mellow Hope is the biggest exporter of Biological Vaccines in China, and has a product line that encompasses vaccines for influenza, tetanus, diphtheria and other diseases; Blood based products including human rabies immunoglobulin; and active pharmaceutical ingredient (or APIs) for injection such as celestatin.

Mellow Hope revenues are currently in excess of $15 million USD, and growing.

Interim company CEO Keith Roberts noted "We think there are going to be strong synergies between our European division and Mellow Hope. Mellow Hope brings a substantial pharmaceutical production and testing capability to the forefront of the Company. In turn, HTDS can provide vital and meaningful assistance to Mellow Hope in developing its export business to Europe and beyond".

Based on initial negotiations, the company anticipates having a formal Letter of Intent in place within a week to ten days, and will provide additional updates on developments as they unfold.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

Wellstar/TMI Announces Pending Pressure Ulcer Study on Leg and Foot Ulcers

HOLLAND, OH--(MARKET WIRE)--Jan 14, 2009 -- Wellstar International, Inc. (OTC BB:WLSI.OB - News), a provider of specialized diagnostic software and equipment, announced today that its wholly owned subsidiary, Trillennium Medical Imaging ("TMI"), has begun negotiations for a pressure ulcer study focused on ulcers caused by diabetic foot and venous legs. The Company is currently in talks with several major teaching and research universities, the goal of which is to secure a clinical partner for this study. Wellstar anticipates that the study could start as early as March 2009.
In the U.S. alone, approximately 1.5 million adults are treated each year for pressure ulcers (bedsores) with associated health care costs of over $5 billion. Regrettably, more than 65,000 patients die each year from complications related to these ulcers. Pressure ulcers represent one of four of the most common and costly deficiencies found in long-term care facilities.

A diabetic foot ulcer is a sore or wound that often occurs in people with diabetes; these ulcers may be difficult to heal, susceptible to infection and may lead to amputation of the affected toe, foot or leg if not treated. Over 850,000 chronic diabetic ulcers are diagnosed in the U.S. each year. Approximately 3 million diabetic patients will develop an ulcer and 25% of these patients will have a foot amputated.

Venous leg ulcer is a sore or wound that is caused by poor circulation of blood in the veins of the legs usually caused by faulty valves allowing pressure to build up in the veins. This pressure causes damage to the tiny blood vessels in the skin, making the skin become thin and inflamed, and causing the death of tissue cells leading to the ulcer.

The Company's infrared imaging system involves the detection and recording of skin temperature and injury patterns, providing visual and quantitative documentation to accurately capture body temperature data. The Company's system map changes in skin blood flow by translating temperature data into pictures. The interpretation of these temperatures and thermal patterns can play an important role in detecting these sores at an early stage.

Wellstar/TMI CEO John Antonio stated, "We are looking forward to working with one of the clinical partners that we are currently communicating with about this planned study. Early detection of pressure ulcers is critical and can actually help prevent ulcer outbreaks among patients. The TMI infrared imaging system is a viable tool, and should soon prove to be the medical standard for predicting and preventing pressure ulcers in the medical community. "

ABOUT WELLSTAR INTERNATIONAL, INC.

Wellstar International, Inc., through its wholly owned operating subsidiary Trillennium Medical Imaging, Inc. (TMI), is poised to become a leading diagnostic company in the health care industry. TMI has developed and is marketing fully calibrated and functional, thermal imaging systems that utilize state-of-the-art infrared technologies and proprietary software to accurately and cost-effectively measure physiological changes in the human body. More information on the Company and its unique diagnostic software and product line is available on Wellstar's corporate Website by visiting: www.wellstar.us

FORWARD-LOOKING STATEMENTS

This press release contains statements, which may constitute 'forward-looking statements' within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Paivis, Corp. Confirms Shareholders to Receive, Through Dividend, Shares of Mistral Ventures, Inc. Upon Finalization of Planned Spin-Off

ATLANTA, GA--(MARKET WIRE)--Jan 14, 2009 -- Paivis, Corp. (Other OTC:PAVC.PK - News) ("PAIVIS" or the "Company") today confirms its intention to dividend shares of Mistral Ventures, Inc. to Paivis' shareholders. This dividend would be planned to take place upon the finalization of the spin-off transaction.
As stated previously, management is committed to providing shareholder value in this challenging economic environment. The Company's reasons for executing a spin-off transaction of this type include among other things, to dividend the shares of the public company Mistral Ventures, Inc. to Paivis' existing shareholders and to take advantage of strategic opportunities without taking on additional debt.

About Paivis, Corp.

Paivis, Corp. is a wholesale telecommunications carrier that sells prepaid "point-of-sale activated" and live cards. Paivis generates its revenues through the sale of prepaid calling cards and wireless services, and international wholesale termination. Products are sold throughout many of the country's major retail outlets.

FORWARD-LOOKING STATEMENTS

The Private Securities Litigation Reform Act of 1995 (the "PSLRA") provides a "safe harbor" for forward-looking statements so long as those statements are identified as forward looking and are accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those projected in such statements.

Statements contained herein that are not based on historical fact, as well as other statements including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "will," "could" and other similar expressions, constitute forward-looking statements under the PSLRA. PAIVIS intends that such forward-looking statements be subject to the safe harbor created thereby. Such forward-looking statements are based on current assumptions but involve known and unknown risks and uncertainties that may cause PAIVIS' actual results, performance or achievements to differ materially from current expectations.

Tuesday, January 13, 2009

Paivis, Corp. Expects Planned Spin-Off Transaction to Boost Shareholder Value

ATLANTA, GA--(MARKET WIRE)--Jan 13, 2009 -- Paivis, Corp. (Other OTC:PAVC.PK - News) ("PAIVIS" or the "Company") today provides additional information to its shareholders about the intended benefits from its planned spin-off of part of its operations into another public company.
The Company's reasons for executing a spin-off transaction of this type include among other things, to dividend the shares of this new public company to Paivis' existing shareholders and to take advantage of strategic opportunities without taking on additional debt.

The Company believes this dividend strategy is a great mechanism to boost shareholder value.

About Paivis, Corp.

Paivis, Corp. is a wholesale telecommunications carrier that sells prepaid "point-of-sale activated" and live cards. Paivis generates its revenues through the sale of prepaid calling cards and wireless services, and international wholesale termination. Products are sold throughout many of the country's major retail outlets.

FORWARD-LOOKING STATEMENTS

The Private Securities Litigation Reform Act of 1995 (the "PSLRA") provides a "safe harbor" for forward-looking statements so long as those statements are identified as forward looking and are accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those projected in such statements.

Statements contained herein that are not based on historical fact, as well as other statements including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "will," "could" and other similar expressions, constitute forward-looking statements under the PSLRA. PAIVIS intends that such forward-looking statements be subject to the safe harbor created thereby. Such forward-looking statements are based on current assumptions but involve known and unknown risks and uncertainties that may cause PAIVIS' actual results, performance or achievements to differ materially from current expectations.

Sunday, January 11, 2009

Nexia Set to Acquire Seven Residential Properties in Northern Utah

SALT LAKE CITY, UT--(MARKET WIRE)--Jan 9, 2009 -- Nexia Holdings, Inc. (OTC BB:NXHD.OB - News) reported that the new management of Wasatch Capital Corporation has identified seven new properties for acquisition under the real estate acquisition strategy being implemented under Richard Surber's direction. The total value of the properties is estimated to be $1.6 million and the company is currently conducting reviews and due diligence on the properties to establish the final purchase numbers and condition of the individual properties. The properties range in estimated value from $90,000 to $480,000 and are all located in the northern Utah area, from the Salt Lake Valley north to Ogden, Utah.
Richard Surber, CEO of Nexia Holdings, stated, "These acquisitions would bring our residential property holdings up to a total of 10 properties and I believe that the growth of our portfolio would make future acquisitions easier. The success and future operations of Wasatch Capital Corporation under its new management utilizing our real estate acquisition strategy appear to be on track."

About Nexia Holdings Inc.

Nexia Holdings Inc. (OTC BB:NXHD.OB - News), headquartered in Salt Lake City, Utah, is a diversified holdings company with operations in real estate, health & beauty, and fashion retail. Nexia, through its subsidiary Green Endeavors, LTD (Other OTC:GRNE.PK - News), www.green-endeavors.com, owns a majority interest in Landis Lifestyle Salon, www.landissalons.com, a hair salon built around the world-class AVEDA(TM) product line. Through its Style Perfect, Inc. subsidiary, Nexia owns the innovative retail and design firm Black Chandelier and its related brands. Black Chandelier currently operates one retail location and online store at www.blackchandelier.com. For more information, visit us at www.nexiaholdings.com.

Nexia strongly encourages the public to read the above information in conjunction with its Form 10-K for December 31, 2007 and the subsequent quarters of 2008. Nexia's disclosures can be viewed at www.nexiaholdings.com and www.sec.gov. The success of the real estate acquisition strategy is conditioned upon a substantial increase in liquidity of Nexia's common stock, an eventual recovery in the real estate markets that Nexia invests in, and many other factors which will emerge as Nexia executes upon its acquisition strategy.

Thursday, January 8, 2009

Wellstar/TMI Begins Marketing Imaging System to Long-Term Care Facilities

HOLLAND, OH--(MARKET WIRE)--Jan 8, 2009 -- Wellstar International, Inc. (OTC BB:WLSI.OB - News), a provider of specialized diagnostic software and equipment, announced today that its wholly-owned subsidiary, Trillennium Medical Imaging ("TMI"), is ready to begin marketing its thermal imaging system to long-term care ("LTC") facilities in the United States. National statistics currently show that the incidence rate of pressure ulcers, also known as bed sores, is as high as 28% of the population for those living in LTC facilities; with many leading experts believing the rate is even higher.
LTC facilities generally care for patients that are critically and/or terminally ill, bed-ridden, and that show higher rates of dementia; all indicators that put an individual at risk for developing a pressure ulcer. TMI's thermal imaging diagnostic device will equip caregivers at these facilities with the ability to objectively identify patterns of injury associated with the development of pressure ulcers. This kind of early detection can lead to intervention and even prevention. By identifying the tissue changes associated with the development of these wounds prior to skin breakdown, a patient can receive considerably better care by avoiding a pressure ulcer occurrence altogether. When long-term care facilities reduce the occurrence of pressure ulcers within their facility, they receive a higher rating in the pay for performance ("P4P") initiative from the Centers for Medicare & Medicaid Services ("CMS").

LTC facilities that utilize TMI's thermal imaging system technology will be able to provide better overall patient care by significantly lowering their pressure ulcer incident rate. By having complete documentation of every skin assessment performed, an LTC facility can also curtail its liabilities by protecting itself against costly lawsuits.

With nearly 16,000 long-term care facilities in the United States, and an aging population that is increasing in size year after year, TMI has an enormous and largely untouched market to go after with its revolutionary system. TMI's marketing plan includes a program where LTC facilities can lease the equipment necessary to perform skin assessments and store the necessary data onsite. Lease plans start at the monthly fee of $2,000 per unit. This monthly fee allows for unlimited imaging, a factor that should help promote aggressive imaging/assessment programs by these facilities.

Wellstar/TMI CEO, John Antonio, commented: "We have already seen a positive response to our thermal imaging system among the LTC facilities we have been engaged with. We expect significant revenue potential within the LTC market, and the Company anticipates placing initial units within these facilities sometime within the first quarter of 2009."

The company has developed its thermal imaging system for various applications. The TMI technology and software has been approved by the FDA as an Adjunctive Diagnostic Screening Procedure for early breast cancer detection, differential diagnoses of pain dysfunctions (such as Reflex Sympathetic Dystrophy, Neuromuscular Skeletal Syndromes and neurological disorders), for the early detection of pressure ulcers, deep tissue injuries, and bedsores, as well as for orthopedic applications. The company has plans to market diagnostic systems for all of the above mentioned applications.

ABOUT WELLSTAR INTERNATIONAL, INC.:

Wellstar International, Inc., through its wholly owned operating subsidiary Trillennium Medical Imaging, Inc. (TMI), is poised to become a leading diagnostic company in the health care industry. TMI has developed and is marketing fully calibrated and functional, thermal imaging systems that utilize state-of-the-art infrared technologies and proprietary software to accurately and cost-effectively measure physiological changes in the human body. More information on the Company and its unique diagnostic software and product line is available on Wellstar's corporate Website, by visiting: www.wellstar.us.

FORWARD-LOOKING STATEMENTS:

This press release contains statements, which may constitute 'forward-looking statements' within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Wednesday, January 7, 2009

Hard To Treat Diseases (HTDS) Set To Acquire Cosmetics Company

CLEARWATER, FL, Jan. 7 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com the company is pleased to announce that it has identified a cosmetics company as a potential merger candidate. The cosmetics company also located in E Europe (Serbia) is engaged in online sales of the "Melem" product. Melem is a versatile, all-purpose skin and lip balm. It has a wide variety of skin and lip problems including eczema, psoriasis, chapped skin and lips, calluses, sunburns, insect bites and much more.
Andrea Rubio Zecevic, who currently acts as a head scientific advisor to HTDS said "Just to be clear, the Melem cosmetics company is not the core business of HTDS by any stretch of the imagination. It's a small self supporting cosmetics company and a nice add on for HTDS. The opportunities in this region due to the Balkan wars of the 1990s are enormous. There are various European Union reconstruction programs and enticements in place while the whole country is in the process of privatizing its entire infrastructure. Just to give our readers an example, HTDS will pay for the Melem cosmetics company a sum equivalent to a price of a USA based mid-sized car. This includes all the formulas, packaging the good will, the client base and whole back office. This is a fraction of the reproduction cost had we bought a similar company just 300-400 miles west in Switzerland or Austria or any other western European country. The company will complete the transaction on all cash basis. Currently this region of the world is celebrating the Orthodox Christmas. As soon as these holidays are behind them, we expect the final documents will be executed and the merger company name announced. In addition we are in contact with the Chief Scienist Dr. Sanja Pekovic who will shortly after the holidays commence furnishing us with regular updates on the progress her team has made with their work (see www.slavicabiochem.com for details). Our aspirations for the merger with the Chinese based medical company engaged in the similar research as Slavica continues. The synergies are definitely present. Our representatives will be in Beijing next week and we should have some preliminary news to report on that front as well."

The company will provide further details as they become available.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

Monday, January 5, 2009

Nexia Reports Salon Revenues of $2,113,943

SALT LAKE CITY, UT--(MARKET WIRE)--Jan 5, 2009 -- Nexia Holdings, Inc. (OTC BB:NXHD.OB - News) (Other OTC:GRNE.PK - News) reported that it generated a total of $2,113,943 (unaudited) in gross salon revenues for the year 2008.
Landis Salons, Inc. now held by Green Endeavors Ltd. (Other OTC:GRNE.PK - News), www.green-endeavors.com, a majority owned subsidiary of Nexia, reported gross revenue growth of 4.2% to $2,113,943 in 2008 compared to $2,025,281 reported for the same period of 2007.

The Salt Lake City Landis salon generated revenues of $1,829,381 (unaudited), a 2.7% decrease for 2008 compared to $1,879,798 reported the same period in 2007. The Bountiful Landis Salon's revenues for 2008 were $284,562 (unaudited), a 48.9% increase from the reported 2007 revenues of $145,483; this salon was acquired by Nexia during August of 2007.

Richard Surber, President and CEO of Nexia, stated, "I am pleased to report that our salon operations have shown resilience during an economically challenging time. The number of services performed actually increased during 2008. We did see a dip in product sales. We are laying the groundwork for expansion and profitability in 2009 for our salons. More information will be forthcoming as our accounting staff gears up for filing Nexia's annual report."

About Nexia Holdings, Inc.

Nexia Holdings, Inc. (OTC BB:NXHD.OB - News), headquartered in Salt Lake City, Utah, is a diversified holdings company with operations in real estate, health & beauty, and fashion retail. Nexia, through its subsidiary Green Endeavors Ltd (Other OTC:GRNE.PK - News) www.green-endeavors.com, owns a majority interest in Landis Lifestyle Salon, www.landissalons.com, a hair salon built around the world-class AVEDA(TM) product line. Through its Style Perfect, Inc. subsidiary, Nexia owns the innovative retail and design firm Black Chandelier and its related brands. Black Chandelier currently operates one retail location and online store at www.blackchandelier.com. For more information, visit www.nexiaholdings.com.

Nexia strongly encourages the public to read the above information in conjunction with its Form 10-K for December 31, 2007 and the subsequent quarters of 2008. Nexia's disclosures can be viewed at www.nexiaholdings.com and www.sec.gov.

This press release reports information gathered on a preliminary basis for the salon operations during 2008, the numbers are not audited, have not been reviewed by an independent accountant and are subject to change and further review as more information is gathered. The information does not reflect costs of operations and does not predict profitable operations for Nexia and its subsidiaries. This press release also contains forward-looking statements. There are no assurances that such assumptions will prove correct. These forward-looking statements involve a number of risks and uncertainties, including an expectation of substantial increase in sales. The actual results that Nexia Holdings may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.

Hard To Treat Diseases (HTDS) Completes E Europe Merger

CLEARWATER, FL, Jan. 5 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com Further to the company's various merger updates where amongst other things the company addressed several targeted merger candidates, the company is pleased to announce that it has finalized its bilateral negotiations with Slavica Bio Chem, www.slavicabiochem.com (Slavica).
Slavica Bio Chem is a spin off of Renuyu Biochem, a USA and a UK company, founded by Andrea Zecevic. Andrea currently acts as a head scientific advisor to HTDS. The company research and development dates back to 2005. The institute and the physical plant is located in Belgrade Serbia. The company has been completely self funding with private resources since its inception. Over the next several weeks Slavica management and its officers intend to provide a series of filings and updates on the company's efforts and progress in this field.

Under the agreement the medical team will receive payment in stock and options on HTDS security on a delivery and performance based schedule. Consideration for Slavica is 300 million non-dilatable restricted shares to be distributed amongst all doctors involved in Belgrade Serbia research. Andrea Zecevic, as a vote of confidence in Slavica and who spearheaded the transaction, shall receive no stock in this transaction and in lieu will take stock options at a .03c strike price for up to 9% of the company common stock.

In other corporate news, the company representatives intend to visit mainland China for a second merger company discussions with a China based company in a similar field and research as Slavica with a significant operations already in place in China. Upon completion of the China merger, the company intends to name its new CEO, officers and directors consisting primarily of medical professionals and business consultants.

The company will provide further details as they become available.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

Sunday, January 4, 2009

Hard To Treat Diseases (HTDS) Pending Merger Update

CLEARWATER, FL, Jan. 2 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com Further to the company's news release of December 30, 2008 where amongst other things the company addressed the targeted merger candidate, firstly the company is pleased to announce that it has appointed its new Chief Science Consultant.
The director of research and business development for the company is Andrea Zecevic Rubio. Andrea is a University of Toronto graduate specializing in the field of Microbiology. Andrea has worked for Pasteur Meriuex Connaught Laboratories (Now Aventis) for several years as a microbiologist, before starting her own consulting business in the field of medical research, and software developments in non medical fields. Andrea is fluent in several languages, such as Spanish, Italian, Portuguese, and English which the company will draw upon with International clients.

Andrea's mandate with HTDS is to research target merger companies in the medical sector that have great potential in bringing valuable products that can make a difference into the market and merging them with HTDS. In addition, Andrea's tasks will include consulting the HTDS management and board directors on the validity of medical operations in the capacity of scientific areas only.

Andrea has identified a suitable merger operating candidate. The merger candidate is a China based bio chemical company.

Andrea said "Currently we have sent two company representatives to examine a company in China that is currently the leading and the largest manufacturer and exporter of vaccines in China offering Hepatitis A Vaccine, Rabies Virus Vaccine, Influenza Virus Vaccine, Polio Vaccine, along with some pharmaceutical raw materials.

In addition, we have entered into a contract with several European companies that are currently at various stages of product launching, from a successful clinical trials stage, to a ready to launch product stage.

The European companies we have examined are currently focused on the chemical repair of damage to the CNS (central nervous system), MS (Multiple Sclerosis) SARS, Hepatitis C, HIV through the enhancement of already approved drugs such as "Virazole" and Tiazofurin.

We also have serious interest in a product that utilizes a natural human body defense from foreign substances as microorganisms, tumors, and antigenes. Beside antiviral effects, the product plays an important role in the battle against various tumors and diabetes."

For scientific dialogue and inquiry only Andrea can be reached via e mail at azconsulting2001@gmail.com. For any corporate matters the readers should contact the company directly at corporate@htdsmedical.com.

In other corporate updates, the company has completed a filing on Pink Sheets re China Medical company. This is a scrubbed version (relevant merger company named removed) until the transaction is closed. The company will post the East European merger candidate shortly.

The company will provide further details as they become available.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

Disclaimer

Average Joe's Picks is an independent electronic medium, which provides industry data and information on publicly traded companies for the use of our readers. Furthermore, the provided data should not be used as the sole basis for making any investment decision. The individual investor's own due diligence is of the utmost importance and highly recommended.